secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001062822-24-000023
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q1 net loss $48.4M; INPEFA sales $1.1M, up 63% QoQ
----------------------------------------------------------

- Net loss of $48.4M ($0.20 per share) vs $31.9M ($0.17) in Q1 2023; SG&A jumped to $32.1M on launch spending.
- Revenue of $1.1M from INPEFA (sotagliflozin) heart failure launch; market access ~40%, expansion expected H2 2024.
- Cash and investments $355.6M as of March 31, up from $170M due to convertible preferred stock issuance in March.
- NDA resubmission for ZYNQUISTA in type 1 diabetes with CKD expected mid-2024; Phase 3 for HCM to start mid-2024.
- Enrollment on track for Phase 2b PROGRESS study of LX9211 in DPNP; topline data expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000023/0001062822-24-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000023/lxrx-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer